| 摘要 |
The present invention relates to a novel soluble biomarker for insulin resistance: 1-methyl nicotinamide (MNA). The invention relates to methods of determining the degree of insulin resistance in a patient. The invention further relates to methods for determining whether a subject with insulin resistance or type 2 diabetes will benefit from a treatment with an inhibitor of nicotinamide-N-methyltransferase (NNMT) or whether a subject responds to a therapeutic treatment with an NNMT inhibitor. The invention also relates to methods of adjusting the dose of an NNMT inhibitor applied for therapeutic treatment of insulin resistance or type-2 diabetes |
